Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy
| dc.contributor.author | Gudena, Ravindra | |
| dc.contributor.author | Werle, Jason | |
| dc.contributor.author | Johnston, Kelly | |
| dc.date.accessioned | 2018-09-27T11:59:50Z | |
| dc.date.available | 2018-09-27T11:59:50Z | |
| dc.date.issued | 2011-05-05 | |
| dc.date.updated | 2018-09-27T11:59:49Z | |
| dc.description.abstract | Osteoporosis-related fractures are a major public health problem and one in two women and one in four men are affected with osteoporosis-related fractures. Alendronate (Fosamax) is one of the first bisphosphonates used to treat osteoporosis effectively. Recently, however, there is a concern regarding long bone insufficiency fractures related to long-term alendronate therapy. We report a case of bilateral femoral insufficiency fractures likely related to long-term alendronate therapy, the classic symptoms, signs, and treatment of these fractures. | |
| dc.description.version | Peer Reviewed | |
| dc.identifier.citation | Ravindra Gudena, Jason Werle, and Kelly Johnston, “Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy,” Journal of Osteoporosis, vol. 2011, Article ID 810697, 4 pages, 2011. doi:10.4061/2011/810697 | |
| dc.identifier.doi | https://doi.org/10.4061/2011/810697 | |
| dc.identifier.uri | http://hdl.handle.net/1880/108424 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/45139 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | Copyright © 2011 Ravindra Gudena et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
| dc.title | Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy | |
| dc.type | Journal Article |